A Phase 2 interventional study of Formoterol Fumarate in the Pressair DPI, Low Dose and Formoterol Fumarate in the Pressair DPI, High Dose in Asthma, sponsored by AstraZeneca. Completed at 29 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-28.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies testing formoterol in Asthma — 2 open to participants now, 2 under way, 2 of them phase 3. formoterol · Asthma.
Among the 86 studies testing formoterol in Asthma, this one is the 40th largest by enrollment of the 85 interventional ones that give a count, is one of 3 that started in 2012, is one of 17 in phase 2, and was the 60th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →2 of the 86 studies testing formoterol in Asthma are open now, in 2 countries. Recruiting first, the newest first:
University of KwaZulu · Sites in South Africa
Ages 6–18
Franciscus Gasthuis · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 174 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 100 across the 85 interventional studies. Of the 76 that completed or were terminated, 29 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 86 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 125th largest by enrollment of the 248 interventional ones that give a count, is one of 7 that started in 2012, is one of 50 in phase 2, and was the 169th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
None of the studies under way reaches primary completion within a year.
Among the 86 studies testing formoterol in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
The purpose of this Phase II study is to evaluate efficacy and safety of inhaled formoterol fumarate in the Pressair DPI compared to the Foradil Aerolizer in patients with mild to moderate asthma.
This study will include a screening visit followed by a 4 month treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Formoterol Fumarate in the Pressair Pressair Dry Powder Inhaler (DPI), Low Dose
Drug: Formoterol Fumarate in the Pressair DPI, Low Dose
Formoterol fumarate in the Pressair Dry Powder Inhaler (DPI), High Dose
Drug: Formoterol Fumarate in the Pressair DPI, High Dose
Foradil Aerolizer, Low Dose
Drug: Foradil Aerolizer, Low Dose
Foradil Aerolizer, High Dose
Drug: Foradil Aerolizer, High Dose
Dose matched placebo
Drug: Placebo
Formoterol Fumarate in the Pressair DPI 6 micrograms, twice a day for 14 days
Formoterol Fumarate in the Pressair DPI 12 micrograms, twice a day for 14 days
Foradil Aerolizer 12 micrograms, twice a day for 14 days
Also known as: Formoterol
Foradil Aerolizer 24 micrograms, twice per day for 14 days
Also known as: Formoterol
Placebo in the Pressair for 14 days
Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) AUC0-6 After the Morning Dose (Day 14)
AUC0-6 is area under the curve from time 0 to 6 hours Serial spirometry was performed at -60 min predose, at 5 (+5) and 30 (±5) min post-dose, and at 1, 2, 3, 4, and 6 hrs post-dose (±15 min) Change from baseline was baseline of each treatment period The normalized FEV1 AUC0-6 was calculated by means of the trapezoidal method, dividing the area under the curve by the corresponding time intervals
Time frame: Baseline and up to 6 hrs post-dose (±15 min) on Day 14 of treatment
Change From Baseline in Normalized FEV1 AUC0-6 After the Morning Dose (Day 1)
AUC0-6 is area under the curve from time 0 to 6 hours Serial spirometry was performed at -60 min predose, at 5 (+5) and 30 (±5) min post-dose, and at 1, 2, 3, 4, and 6 hrs post-dose (±15 min) Change from baseline was baseline of Period 1 The time-normalized FEV1 AUC0-6 was calculated by means of the trapezoidal method, dividing the area under the curve by the corresponding time intervals
Time frame: Baseline and up to 6 hrs post-dose (±15 min) on Day 1 of treatment
The study was conducted in 29 study centers in the United States First patient visit was in June 2012 and last patient visit was in February 2013
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 | Sequence 7 | Sequence 8 | Sequence 9 | Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 18 | 18 | 15 | 22 | 17 | 19 | 19 | 17 | 15 | 14 |
| Completed | 17 | 18 | 15 | 22 | 16 | 19 | 18 | 14 | 15 | 14 |
| Not completed | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 0 | 0 |
| Withdrew: Sponsor request (potential unblinding) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 | Sequence 7 | Sequence 8 | Sequence 9 | Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 17 | 18 | 15 | 22 | 16 | 19 | 18 | 14 | 15 | 14 |
| Completed | 16 | 18 | 15 | 21 | 16 | 18 | 16 | 14 | 15 | 14 |
| Not completed | 1 | 0 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 | Sequence 7 | Sequence 8 | Sequence 9 | Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 16 | 18 | 15 | 21 | 16 | 18 | 16 | 14 | 15 | 14 |
| Completed | 16 | 18 | 14 | 21 | 16 | 18 | 16 | 14 | 14 | 14 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 | Sequence 7 | Sequence 8 | Sequence 9 | Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 16 | 18 | 14 | 21 | 16 | 18 | 16 | 14 | 14 | 14 |
| Completed | 16 | 17 | 14 | 20 | 16 | 18 | 16 | 14 | 14 | 14 |
| Not completed | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 | Sequence 7 | Sequence 8 | Sequence 9 | Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 16 | 17 | 14 | 20 | 16 | 18 | 16 | 14 | 14 | 14 |
| Completed | 16 | 17 | 12 | 20 | 16 | 18 | 16 | 14 | 14 | 14 |
| Not completed | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AUC0-6 is area under the curve from time 0 to 6 hours Serial spirometry was performed at -60 min predose, at 5 (+5) and 30 (±5) min post-dose, and at 1, 2, 3, 4, and 6 hrs post-dose (±15 min) Change from baseline was baseline of each treatment period The normalized FEV1 AUC0-6 was calculated by means of the trapezoidal method, dividing the area under the curve by the corresponding time intervals
| Liters | Foradil 24 μg | Foradil 12 μg | Formoterol 12 μg | Formoterol 6 μg | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) AUC0-6 After the Morning Dose (Day 14) | 0.3196 ± 0.0382 | 0.3076 ± 0.0382 | 0.2795 ± 0.0382 | 0.2726 ± 0.0381 | 0.0552 ± 0.0382 |
AUC0-6 is area under the curve from time 0 to 6 hours Serial spirometry was performed at -60 min predose, at 5 (+5) and 30 (±5) min post-dose, and at 1, 2, 3, 4, and 6 hrs post-dose (±15 min) Change from baseline was baseline of Period 1 The time-normalized FEV1 AUC0-6 was calculated by means of the trapezoidal method, dividing the area under the curve by the corresponding time intervals
| Liters | Foradil 24 μg | Foradil 12 μg | Formoterol 12 μg | Formoterol 6 μg | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Normalized FEV1 AUC0-6 After the Morning Dose (Day 1) | 0.3544 ± 0.0196 | 0.3068 ± 0.0198 | 0.2712 ± 0.0197 | 0.2204 ± 0.0197 | 0.0306 ± 0.0198 |
Collected over Day 14±1 of the final treatment period (Period 5). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Foradil 24 μg | — | 0/167 (0%) | 10/167 (6%) |
| Foradil 12 μg | — | 2/163 (1.2%) | 2/163 (1.2%) |
| Formoterol 12 μg | — | 0/164 (0%) | 2/164 (1.2%) |
| Formoterol 6 μg | — | 0/166 (0%) | 1/166 (0.6%) |
| Placebo | — | 0/165 (0%) | 0/165 (0%) |
| Event | Foradil 24 μg | Foradil 12 μg | Formoterol 12 μg | Formoterol 6 μg | Placebo |
|---|---|---|---|---|---|
| Ankle fractureInjury, poisoning and procedural complications | 0/167 | 1/163 | 0/164 | 0/166 | 0/165 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/167 | 1/163 | 0/164 | 0/166 | 0/165 |
| Event | Foradil 24 μg | Foradil 12 μg | Formoterol 12 μg | Formoterol 6 μg | Placebo |
|---|---|---|---|---|---|
| TremorNervous system disorders | 10/167 | 2/163 | 2/164 | 1/166 | 0/165 |
| Age, Continuous(Years) | Overall Study Population |
|---|---|
| Mean | 45.4 ± 13.2 |
| Gender(Participants) | Overall Study Population |
|---|---|
| Female | 91 |
| Male | 83 |
The record gives a start of Jun 2012, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2016, 3 years 10 months after primary completion. A results delay was requested in Feb 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Formoterol